Advanced search
Publication Cover
Expert Opinion on Drug Discovery Volume 11, 2016 - Issue 7
Submit an article Journal homepage
681
Views
5
CrossRef citations to date
0
Altmetric
Drug Discovery Case History

The discovery of dabigatran etexilate for the treatment of venous thrombosis

Martin FeuringDepartment of Clinical Development & Medical Affairs, Boehringer Ingelheim GmbH & Co. KG, Ingelheim am Rhein, GermanyCorrespondence[email protected]
&
Joanne van RynDepartment of Clinical Development & Medical Affairs, Boehringer Ingelheim GmbH & Co. KG, Ingelheim am Rhein, Germany
Pages 717-731 | Received 29 Jan 2016, Accepted 06 May 2016, Published online: 30 May 2016

Citations (5)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Antonio Gómez-Outes, Minerva García-Fuentes & Mª Luisa Suárez-Gea. (2017) Discovery methods of coagulation-inhibiting drugs. Expert Opinion on Drug Discovery 12:12, pages 1195-1205.
Read now

Articles from other publishers (4)

Syed Waseem Bihaqi, Haripriya Vittal Rao, Abhik Sen & Paula Grammas. (2021) Dabigatran reduces thrombin-induced neuroinflammation and AD markers in vitro: Therapeutic relevance for Alzheimer's disease. Cerebral Circulation - Cognition and Behavior 2, pages 100014.
Crossref
Carlos Escobar, Xavier Borrás, Ramón Bover Freire, Carlos González-Juanatey, Miren Morillas, Alfonso Valle Muñoz & Juan José Gómez-Doblas. (2020) A Delphi consensus on the management of oral anticoagulation in patients with non-valvular atrial fibrillation in Spain: ACOPREFERENCE study. PLOS ONE 15:6, pages e0231565.
Crossref
Manuela Albisetti, Arno Schlosser, Martina Brueckmann, Savion Gropper, Stephan Glund, Igor Tartakovsky, Leonardo R. Brandão & Paul A. Reilly. (2018) Rationale and design of a phase III safety trial of idarucizumab in children receiving dabigatran etexilate for venous thromboembolism. Research and Practice in Thrombosis and Haemostasis 2:1, pages 69-76.
Crossref
Emanuel Raschi, Matteo Bianchin, Walter Ageno, Roberto De Ponti & Fabrizio De Ponti. (2016) Risk–Benefit Profile of Direct-Acting Oral Anticoagulants in Established Therapeutic Indications: An Overview of Systematic Reviews and Observational Studies. Drug Safety 39:12, pages 1175-1187.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.